Biomedtech Approach
We are Business Builders
We have been creating companies to address critical medical and environmental needs, growing technology leaders in MedTech, Biotech and BioEcoTech. Mostly based in France, these companies target global, multibillion-dollar markets.
We source the best innovations worldwide
We work closely with the world's best 50 universities to select, in-license and develop their most recent inventions into novel products.
We save patients’ lives
Strong focus on life-saving therapeutic, minimally-invasive medical devices, interventional autonomous robotics and first-in-class therapeutics.
TRUFFLE BIOMEDTECH ACCELERATOR
A place to grow and collaborate in the heart of Paris
“With its BioMedTech Accelerator, Truffle Capital brings together the best skills and expertise in medical device technologies in a single location. Synergies are strong between the companies, which benefit from shared skills. The aim is to help build up an industry of excellence in France to create leaders in MedTech.”
Dr. Philippe Pouletty, M.D., Co-founder & CEO
2017
Date of Establishment
7
Companies
>60
Employees (including 25 PhDs & 17 nationalities)
MEDEOR FUND
Our latest fund is dedicated to growing European clinical-stage MedTech and Biotech companies
Truffle Capital, as a lead investor, focuses on clinical-stage, interventional, therapeutic MedTech, first-in-class Biotech and industrial BioEcoTech.
What we don’t do: Diagnostics, services, digital health/e-heath, non-European based companies.
PIONNEERING SUSTAINABLE PROGRESS
At the core of the companies
In line with Truffle’s strong commitments on ESG policy, our companies demonstrate strong impact, contributing to saving lives and preserving our planet, based on scientific research and novel technologies, thanks to international and diverse management teams. ESG is at the core of the companies created and supported by Truffle Capital. As for MedTech and Biotech, Truffle Capital's goes beyond financial returns for its investors by improving patients’ health and quality of life. Regarding BioEcoTech, we use science and biotechnologies to promote a circular and sustainable economy.
20
Widespread conditions targeted to improve global health (Stroke, Heart failure, Obesity, Cancer, Infectious diseases, Incontinence…)
2M
An objective of 2M metric tons of CO2 avoided each year (Truffle Portfolio Companies)